ScripJohnson & Johnson is the first big pharma to report first quarter sales and earnings, and thus the first to outline expectations about the impact of tariffs on its financial outlook. So far, J&
ScripVerve Therapeutics is looking to submit its opt-in package to partner Eli Lilly after the announcement of positive data from the Phase Ib study of VERVE-102 in heterozygous familial hypercholesterolem
ScripUS President Donald Trump’s ever-evolving stance on tariffs may be rattling the world and also has pharma on tenterhooks, but going down that path for generic medicines may be a doubled-edged sword or
ScripAs Donald Trump’s threats to impose tariffs on imported pharmaceuticals increase in intensity, the US president will be pleased to hear that Novartis is expanding its manufacturing and R&D footp